PFCS
CDTX

Pale Fire Capital SE’s Cidara Therapeutics CDTX Stock Holding History

Pale Fire Capital SE’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,327
Closed -$61.2K – 49
2024
Q1 		$61.2K Hold
3,327
– – 0.01% 48
2023
Q4 		$52.8K Buy
3,327
+609
+22% +$9.78K 0.01% 71
2023
Q3 		$51.2K Buy
+2,718
New +$53.4K 0.01% 67

Other funds holding CDTX

MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $390M AUM 96.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Pale Fire Capital SE's CDTX Position: Q2 2024 in Review

Pale Fire Capital SE sold out of Cidara Therapeutics (CDTX) in Q2 2024, closing a stake of 3,327 shares — an estimated $61.2K sold.

Pale Fire Capital SE first reported a position in CDTX in Q3 2023 and held it in 3 quarters. The position peaked at $61.2K in Q1 2024. 26 funds tracked by Wall St. Rank hold CDTX as of Q2 2024.

  • Pale Fire Capital SE reported no remaining Cidara Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Pale Fire Capital SE sold 3,327 Cidara Therapeutics shares in Q2 2024, an estimated $61.2K.
  • Pale Fire Capital SE first reported a position in Cidara Therapeutics in Q3 2023 and held it in 3 quarters.
  • Pale Fire Capital SE's Cidara Therapeutics position peaked at $61.2K in Q1 2024.
  • 26 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2024.

Based on Pale Fire Capital SE's 13F filing for Q2 2024, filed 13 Aug 2024.